Comparative benefits and harms of second generation antidepressants and cognitive behavioral therapies in initial treatment of major depressive disorder: systematic review and meta-analysis

被引:130
|
作者
Amick, Halle R. [1 ]
Gartlehner, Gerald [2 ,3 ]
Gaynes, Bradley N. [4 ]
Forneris, Catherine [4 ]
Asher, Gary N. [5 ]
Morgan, Laura C. [2 ]
Coker-Schwimmer, Emmanuel [1 ]
Boland, Erin [2 ]
Lux, Linda J. [2 ]
Gaylord, Susan [6 ]
Bann, Carla [2 ]
Pierl, Christiane Barbara [3 ]
Lohr, Kathleen N. [2 ]
机构
[1] Univ N Carolina, Sheps Ctr Hlth Serv Res, Chapel Hill, NC 27599 USA
[2] RTI Int, Res Triangle Pk, NC 27709 USA
[3] Danube Univ, Dept Evidence Based Med & Clin Epidemiol, A-3500 Krems, Austria
[4] Univ N Carolina, Dept Psychiat, Chapel Hill, NC 27599 USA
[5] Univ N Carolina, Dept Family Med, Chapel Hill, NC 27599 USA
[6] Univ N Carolina, Dept Phys Med & Rehabil, Chapel Hill, NC 27599 USA
来源
基金
美国医疗保健研究与质量局;
关键词
PRIMARY-CARE PATIENTS; TREATMENT PREFERENCES; TREATING DEPRESSION; ANXIETY DISORDERS; RANDOMIZED-TRIAL; PSYCHOTHERAPY; MEDICATION; PHARMACOTHERAPY; HEALTH; ACTIVATION;
D O I
10.1136/bmj.h6019
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
STUDY QUESTION What are the benefits and harms of second generation antidepressants and cognitive behavioral therapies (CBTs) in the initial treatment of a current episode of major depressive disorder in adults? METHODS This was a systematic review including qualitative assessment and meta-analyses using random and fixed effects models. Medline, Embase, the Cochrane Library, the Allied and Complementary Medicine Database, PsycINFO, and the Cumulative Index to Nursing and Allied Health Literature were searched from January1990 through January 2015. The 11 randomized controlled trials included compared a second generation antidepressant CBT. Ten trials compared antidepressant monotherapy with CBT alone; three compared antidepressant monotherapy with antidepressant plus CBT. SUMMARY ANSWER AND LIMITATIONS Meta-analyses found no statistically significant difference in effectiveness between second generation antidepressants and CBT for response (risk ratio 0.91, 0.77 to 1.07), remission (0.98, 0.73 to 1.32), or change in 17 item Hamilton Rating Scale for Depression score (weighted mean difference, -0.38, -2.87 to 2.10). Similarly, no significant differences were found in rates of overall study discontinuation (risk ratio 0.90, 0.49 to 1.65) or discontinuation attributable to lack of efficacy (0.40, 0.05 to 2.91). Although more patients treated with a second generation antidepressant than receiving CBT withdrew from studies because of adverse events, the difference was not statistically significant (risk ratio 3.29, 0.42 to 25.72). No conclusions could be drawn about other outcomes because of lack of evidence. Results should be interpreted cautiously given the low strength of evidence for most outcomes. The scope of this review was limited to trials that enrolled adult patients with major depressive disorder and compared a second generation antidepressant with CBT, and many of the included trials had methodological shortcomings that may limit confidence in some of the findings. WHAT THIS STUDY ADDS Second generation antidepressants and CBT have evidence bases of benefits and harms in major depressive disorder. Available evidence suggests no difference in treatment effects of second generation antidepressants and CBT, either alone or in combination, although small numbers may preclude detection of small but clinically meaningful differences.
引用
收藏
页数:10
相关论文
共 50 条
  • [41] Adjunctive cariprazine for major depressive disorder: a systematic review and meta-analysis
    Gill, Hartej
    Chen-Li, David C. J.
    Haikazian, Sipan
    Seyedin, Sam
    McIntyre, Roger S.
    Mansur, Rodrigo B.
    DiVincenzo, Joshua D.
    Phan, Lee
    Rosenblat, Joshua D.
    CNS SPECTRUMS, 2024, 29 (04) : 233 - 242
  • [42] Effectiveness of yoga for major depressive disorder: A systematic review and meta-analysis
    Wu, Yufei
    Yan, Danni
    Yang, Jianli
    FRONTIERS IN PSYCHIATRY, 2023, 14
  • [43] Prospective biomarkers of major depressive disorder: a systematic review and meta-analysis
    Kennis, Mitzy
    Gerritsen, Lotte
    van Dalen, Marije
    Williams, Alishia
    Cuijpers, Pim
    Bockting, Claudi
    MOLECULAR PSYCHIATRY, 2020, 25 (02) : 321 - 338
  • [44] Epidemiology of Major Depressive Disorder in Iran: A Systematic Review and Meta-Analysis
    Sadeghirad, Behnam
    Haghdoost, Ali-Akbar
    Amin-Esmaeili, Masoumeh
    Ananloo, Esmaeil Shahsavand
    Ghaeli, Padideh
    Rahimi-Movaghar, Afarin
    Talebian, Elham
    Pourkhandani, Ali
    Noorbala, Ahmad Ali
    Barooti, Esmat
    INTERNATIONAL JOURNAL OF PREVENTIVE MEDICINE, 2010, 1 (02) : 81 - 91
  • [45] Comorbid Major Depressive Disorder in Schizophrenia: A Systematic Review and Meta-Analysis
    Etchecopar-Etchart, Damien
    Korchia, Theo
    Loundou, Anderson
    Llorca, Pierre-Michel
    Auquier, Pascal
    Lancon, Christophe
    Boyer, Laurent
    Fond, Guillaume
    SCHIZOPHRENIA BULLETIN, 2021, 47 (02) : 298 - 308
  • [46] Gut microbiota and major depressive disorder: A systematic review and meta-analysis
    Sanada, Kenji
    Nakajima, Shinichiro
    Kurokawa, Shunya
    Barcelo-Soler, Alberto
    Ikuse, Daisuke
    Hirata, Akihito
    Yoshizawa, Akira
    Tomizawa, Yoshihiro
    Salas-Valero, Montserrat
    Noda, Yoshihiro
    Mimura, Masaru
    Iwanami, Akira
    Kishimoto, Taishiro
    JOURNAL OF AFFECTIVE DISORDERS, 2020, 266 : 1 - 13
  • [47] Cortical thickness in major depressive disorder: A systematic review and meta-analysis
    Suh, Jee Su
    Schneider, Maiko Abel
    Minuzzi, Luciano
    MacQueen, Glenda M.
    Strother, Stephen C.
    Kennedy, Sidney H.
    Frey, Benicio N.
    PROGRESS IN NEURO-PSYCHOPHARMACOLOGY & BIOLOGICAL PSYCHIATRY, 2019, 88 : 287 - 302
  • [48] Antipsychotic Monotherapy for Major Depressive Disorder: A Systematic Review and Meta-Analysis
    Nishi, Akira
    Sawada, Kyosuke
    Uchida, Hiroyuki
    Mimura, Masaru
    Takeuchi, Hiroyoshi
    PHARMACOPSYCHIATRY, 2023, 56 (01) : 5 - 17
  • [49] Prospective biomarkers of major depressive disorder: a systematic review and meta-analysis
    Mitzy Kennis
    Lotte Gerritsen
    Marije van Dalen
    Alishia Williams
    Pim Cuijpers
    Claudi Bockting
    Molecular Psychiatry, 2020, 25 : 321 - 338
  • [50] Neuropsychological Assessments of Cognitive Impairment in Major Depressive Disorder: A Systematic Review and Meta-Analysis with Meta-Regression
    Rhee, Taeho Greg
    Shim, Sung Ryul
    Manning, Kevin J.
    Tennen, Howard A.
    Kaster, Tyler S.
    d'Andrea, Giacomo
    Forester, Brent P.
    Nierenberg, Andrew A.
    Mcintyre, Roger S.
    Steffens, David C.
    PSYCHOTHERAPY AND PSYCHOSOMATICS, 2024, 93 (01) : 8 - 23